BHC INVESTOR ALERT

Robbins Geller Rudman & Dowd LLP Announces that Bausch Health Companies Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Bausch Health Companies Inc. (NYSE: BHC) securities between August 6, 2020 and May 3, 2023, both dates inclusive (the “Class Period”) have until September 25, 2023 to seek appointment as lead plaintiff of the Bausch Health class action lawsuit. Captioned Kelk v. Bausch Health Companies Inc., No. 23-cv-03996 (D.N.J.), the Bausch Health class action lawsuit charges Bausch Health and certain of its top current and former executive officers with violations of the Securities Exchange Act of 1934.

If you suffered substantial losses and wish to serve as lead plaintiff of the Bausch Health class action lawsuit, please provide your information here:

https://www.rgrdlaw.com/cases-bausch-health-companies-inc-class-action ...

You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at [e-mail]. Lead plaintiff motions for the Bausch Health class action lawsuit must be filed with the court no later than September 25, 2023.

CASE ALLEGATIONS: Bausch Health is a pharmaceutical company known for its majority ownership of Bausch + Lomb Corporation (“B+L”). In 2016, Bausch Health was forced to replace its senior management and attempt to rebuild its reputation after it was revealed that it had engaged in one of the most egregious cases of securities fraud in U.S. history. Among other things, Bausch Health was forced to restate its financial statements, enter into a settlement with the U.S. Securities and Exchange Commission, and settle a class action with investors for a payment of more than $1.1 billion in November 2019. On August 6, 2020, Bausch Health announced plans to spin-off B+L into its own publicly traded entity. Bausch Health at the time said that the benefits of the spinoff included “improved strategic focus and enhanced financial transparency.”

The Bausch Health class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) the B+L spinoff would not result in two strong separate companies; (ii) without B+L, Bausch Health was left overly leveraged and without the cash flow generated by B+L; (iii) distribution of the B+L spinoff shares would not occur as represented; (iv) Bausch Health omitted and/or concealed the potential damages Bausch Health faced from securities fraud litigation; and (v) the spinoff was not intended to benefit Bausch Health shareholders but instead designed to subvert the securities fraud litigation plaintiffs’ lawsuit against Bausch Health.